TrademarkOpen
Search / United States / 88788692

Heads up: we show every live trademark, plus inactive ones from the last 5 years, in the United States, Singapore, Canada, Australia and France. India is looked up live when you search, so it is not a saved copy of every mark, and it can be busy some days. Data is only as fresh as each country publishes it, and some countries aren’t included yet, so a brand can be registered even if it doesn’t show here. Always check the official record before you use a name. This is not legal advice.

🇺🇸 United States · Trademark / Service Mark

AIM

Allowed — statement of use stage
First Extension - Granted
Used for: Intravenous solution for use in the treatment of viral infections, immune disorders, cancer and ME/CFS; intravenous…
Show more

Class 5: Intravenous solution for use in the treatment of viral infections, immune disorders, cancer and ME/CFS; intravenous solution for use in the treatment of viral infections, immune disorders, cancer and ME/CFS; intravenous solution for use in the treatment of injuries resulting from surgery, thermal accidents or burns; Interferons; Parenterally administered interferon for use in treating viral diseases, immunological disorders and cancer; Pharmaceutical products, namely, pharmaceutical preparations for treatment of viral and infectious diseases, cancer, immune disorders and ME/CFS; intranasal solutions for use as a vaccine adjuvant
Class 42: Pharmaceutical research and development; Pharmaceutical research and development of drugs for the treatment of cancers, viral diseases, immunological disorders and ME/CFS

Class 5 – Pharmaceuticals & supplementsClass 42 – Technology & SaaS

Status timeline

  1. 11 Feb 2020
    Application filed
    New Application Entered
  2. 28 Apr 2020
    Assigned to an examining attorney
    Assigned To Examiner
  3. 4 May 2020
    Office action issued
    Non-Final Action Written
  4. 4 Nov 2020
    Response to office action filed
    Teas Response To Office Action Received
  5. 27 Nov 2020
    Examination suspended
    Suspension Letter Written
  6. 1 Jul 2025
    Approved for publication
    Approved For Pub - Principal Register
  7. 12 Aug 2025
    Published for opposition
    Published For Opposition
  8. 7 Oct 2025
    Notice of allowance issued — statement of use required
    Noa Mailed - Sou Required From Applicant
  9. 6 Apr 2026
    Statement-of-use extension 1 granted
    Sou Extension 1 Granted
All 28 events
2026-04-07Notice Of Approval Of Extension Request E-Mailed
2026-04-06Sou Teas Extension Received
2026-04-06Sou Extension 1 Filed
2026-04-06Sou Extension 1 Granted
2025-10-07Noa Mailed - Sou Required From Applicant
2025-08-12Published For Opposition
2025-08-12Official Gazette Publication Confirmation E-Mailed
2025-08-06Notification Of Notice Of Publication E-Mailed
2025-07-01Suspension Checked - To Attorney For Action
2025-07-01Approved For Pub - Principal Register
2024-12-31Report Completed Suspension Check Case Still Suspended
2024-01-17Report Completed Suspension Check Case Still Suspended
2023-06-15Report Completed Suspension Check Case Still Suspended
2022-11-30Report Completed Suspension Check Case Still Suspended
2022-04-27Report Completed Suspension Check Case Still Suspended
2021-08-20Report Completed Suspension Check Case Still Suspended
2020-11-27Suspension Letter Written
2020-11-27Letter Of Suspension E-Mailed
2020-11-27Notification Of Letter Of Suspension E-Mailed
2020-11-05Teas/Email Correspondence Entered
2020-11-04Teas Response To Office Action Received
2020-11-04Correspondence Received In Law Office
2020-05-04Non-Final Action Written
2020-05-04Non-Final Action E-Mailed
2020-05-04Notification Of Non-Final Action E-Mailed
2020-04-28Assigned To Examiner
2020-02-11New Application Entered
2020-02-11New Application Office Supplied Data Entered

Goods & services by class

Class 5 Pharmaceuticals & supplements

Intravenous solution for use in the treatment of viral infections, immune disorders, cancer and ME/CFS; intravenous solution for use in the treatment of viral infections, immune disorders, cancer and ME/CFS; intravenous solution for use in the treatment of injuries resulting from surgery, thermal accidents or burns; Interferons; Parenterally administered interferon for use in treating viral diseases, immunological disorders and cancer; Pharmaceutical products, namely, pharmaceutical preparations for treatment of viral and infectious diseases, cancer, immune disorders and ME/CFS; intranasal solutions for use as a vaccine adjuvant

Class 42 Technology & SaaS

Pharmaceutical research and development; Pharmaceutical research and development of drugs for the treatment of cancers, viral diseases, immunological disorders and ME/CFS

Owner details

See the official record for contact details. View official record →

Source & freshness

Source: the official United States trademark register. This record was last updated on 8 Apr 2026; the index was built on 20 Nov 2026 and covers data through 31 Aug 2026. View official record → If the two differ, the official record is correct.